Clinical Trial Update: Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib plus cadonilimab in unresectable or metastatic bile duct adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Adenocarcinoma

Drugs mentioned

• Cadonilimab
• Surufatinib (Surufatinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Bile Duct Adenocarcinoma | Phase 2 | Status: UNKNOWN